Clinical Trial of a Calcium Channel Blocker in Patients with Aneurysmal Subarachnoid Hemorrhage
Yonsei Medical Journal
;
: 126-130, 1987.
Artigo
em Inglês
| WPRIM
| ID: wpr-106499
ABSTRACT
Forty-three patients with aneurysmal subarachnoid hemorrhage entered a nimodipine trial in the Department of Neurosurgery, Yonsei university to determine the efficacy of the drug in preventing vasospasm and to evaluate the tolerability of this calcium channel blocker. Thirty-three patients completed the study. Treatment was started within four days of initial bleeding and continued for two weeks. Delayed neurological deficits developed in seven of the 33 patients-four from vasospasm, two from elevated intracranial pressure, and one from recurrent bleeding. The incidence of symptomatic vasospasm which developed after calcium channel blocker (nimodipine) treatment was 12.1%, which is about one third of the rate experienced at our department during the past five years (33.2%). Twenty-five patients were operated on without surgical mortality and the morbidity rate was 8%. Side effects due to nimodipine treatment were reversible and insignificant. This study suggests that treatment with a calcium channel blocker that has a selective cerebrovascular effect may prevent or reduce the incidence of delayed ischemic deficits in patients with aneurysmal subarachnoid hemorrhage.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Hemorragia Subaracnóidea
/
Nimodipina
/
Ataque Isquêmico Transitório
/
Estudos Prospectivos
/
Ensaios Clínicos como Assunto
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo observacional
Limite:
Humanos
Idioma:
Inglês
Revista:
Yonsei Medical Journal
Ano de publicação:
1987
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS